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Abstract
Systemic injection of a thymidine analogue such as bromodeoxyuridine (BrdU) in vertebrates is commonly used to detect
and study cell production during development, adulthood, and pathology, particularly in studies of adult neurogenesis.
Although researchers are applying this technique to multiple species in various physiological conditions, the rate of BrdU
clearance from the serum remains unknown in most cases. Changes in this clearance rate as a function of the species, sex or
endocrine condition could however profoundly affect the interpretation of the results. We describe a rapid, sensitive, but
simple bioassay for post-injection detection and quantification of BrdU in serum. This procedure was shown to be suitable
for determining the length of time a thymidine analogue remains in the bloodstream of one avian species and seems
applicable to any vertebrate provided sufficiently large blood samples can be collected. This technique was used to
demonstrate that, in canaries, BrdU injected at a dose of 100 mg/kg is no longer available for incorporation into DNA
between 30 and 60 min post-injection, a delay shorter than anticipated based on the available literature. Preliminary data
suggest a similar fast clearance in Japanese quail and mice.
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Introduction
The injection of thymidine analogues such as bromodeoxyur-
idine (BrdU) that are incorporated into DNA during its replication
continues to be the best and most commonly used technique for
investigating proliferating populations of cells in vivo [1], [2]. This
is particularly true in the neurosciences, where injections of BrdU
have been commonly used to assess the rate of neuronal
progenitor proliferation both during ontogeny [3] and in
adulthood [2],[4–6]). In addition, since newly-formed neuronal
precursors very often do not undergo many subsequent divisions
(in particular during adult neurogenesis), the incorporated BrdU
can be used to trace the survival of the new neurons (e.g., [7–11]).
Most studies using bromodeoxyuridine (BrdU) to label mitotic
cells assume a bioavailability time of approximately 2 h after
injection. This is based primarily on early studies that relied on
detecting radioactive thymidine or thymidine analogues in tissue of
mice [12–14], rats [12], and primates [15], [16]. However, there is
little information on the persistence in serum of BrdU or other
thymidine analogues in other species, despite indirect evidence
that this time is not consistent across species. Pregnant rhesus
monkeys, for example, clear tritiated thymidine from plasma
considerably more rapidly than 2 h [16]. It is therefore possible
that there may be species, strain, life stage, or sex differences in
clearance rates that could affect the total number of cells labelled
and have dramatic effects on the interpretation of results from
experiments that include injecting BrdU. Treatments that
influence clearance rates could also affect cell counts indepen-
dently of cell proliferation changes. Multiple studies have for
example identified differences in the number of new neurons
labelled with BrdU as a function of the sex or endocrine conditions
of the subjects (for recent reviews see [17–19]). This could reflect
true differences in the rate of neurogenesis, but undetected
changes in BrdU clearance from the serum could have the same
effect.
As research using these analogues advances, determining the
clearance rate of BrdU or other thymidine analogues quickly and
easily in model organisms of interest is therefore important for the
development of appropriate experimental timelines and protocols,
for confirming successful injection, and for ensuring that detected
differences in proliferation rates are not the result of differential
clearance of the thymidine analogue(s) used. The rate at which
such molecules are cleared from the circulatory system is unknown
for most species, in part because they can be difficult to detect in
solution when not bound to DNA.
Injected thymidine analogues can be detected in a variety of
different ways, including radioassays [12] or high-performance
liquid chromatography (HPLC) [20], [21]. However, the former
requires the in vivo injection of radioactive (typically tritiated)
analogues, appropriate detection equipment, and generating
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substantial amounts of radioactive waste, while the latter
requires specialized equipment specifically calibrated to differ-
entiate the analogue from any endogenous thymidine that may
be present. These technical difficulties mean that BrdU
concentrations in blood are rarely quantified. We therefore
sought to develop a fast, simple and inexpensive method that
would allow for detection and quantification of BrdU in serum
with the need for minimal amounts of equipment. We present
here a bioassay in which we expose living cultured eukaryotic
cells to serum from several species injected with BrdU, and then
allow the cells to incorporate the BrdU from the serum. The
technique then relies on standard immunohistochemical staining
techniques. It thus could be used to detect any thymidine
analogue that is normally detectable in tissue, injected into any
species from which serum can be collected, using any
proliferative eukaryotic cell strain that can be cultured. We
demonstrate the utility of this technique using HEK293T cells
to detect free BrdU in the serum of canaries (Serinus canaria). We
selected this species because studies of canaries arguably played
a key role in initiating the modern era of studies of adult
neurogenesis in vertebrates [22], [23]. We also studied a few
quail and mice, at various time points after BrdU injection to




Six adult canaries (Serinus canaria, 4 males and 2 females) of
mixed-breed origin were obtained from a local breeder (Noorder-
wijk, Belgium). Two adult female Japanese quail (Coturnix japonica)
from an in-house breeding colony (University of Lie`ge, Belgium),
and three adult C57BL6 mice (Mus musculus 2 males and 1 female)
from the central breeding colony at the University of Lie`ge,
Belgium were also used. All experimental procedures complied
with the relevant Belgian laws concerning the Protection and
Welfare of Animals and the Protection of Experimental Animals.
Experimental protocols were approved by the Ethics Committee
for the Use of Animals at the University of Lie`ge (protocol number
926).
BrdU Administration and Sample Collection
A single intraperitoneal injection of BrdU (100 mg/kg, dissolved
in sterile 0.9% saline) was given to each animal. We then collected
in microcentrifuge tubes peripheral blood samples (via brachial
vein puncture in birds, tail vein puncture in mice) 15 min, 30 min,
60 min and 120 min after injection. Four hours (240 min) after
injection, trunk blood samples were taken after animals were
deeply anesthetized and decapitated. Blood was allowed to clot
overnight, centrifuged at 10,000 g for 10 minutes, and the serum
was collected and stored at 220uC until analysis.
Cell Culture
HEK293T cells were cultured on glass coverslips (12 mm
diameter stored in 24 well culture plates) in Dulbecco’s modified
Eagle’s medium (Invitrogen) containing 10% fetal bovine serum
(DMEM+FBS, 500 ml) at 37uC for 24 h. Cultures were then rinsed
and incubated at 37uC in DMEM+FBS for another 4 h with the
addition of either 10 mL of a known concentration (from 0 mg/
mL to 3 mg/mL) of BrdU (dissolved in pooled serum from
uninjected birds, in normal horse serum, or in 0.9% saline), or
10 mL of serum from a subject previously injected with BrdU. The
cultured cells were then immediately processed with immunohis-
tochemistry against BrdU.
Immunohistochemical Staining
Plated cells were rinsed with 0.01 M phosphate-buffered saline
(pH 7.4; PBS), fixed by incubation in 4% formaldehyde in PBS for
20 min, and rinsed three times in PBS. Cells were then incubated
with 0.6% hydrogen peroxide in PBS, rinsed, incubated 10 min in
2N HCl followed by 5 min in 0.1 M sodium borate buffer
(pH 8.5), rinsed again, and blocked 8 min in 10% normal horse
serum in PBS with 0.02% Triton-X100 (PBS-T) followed by
incubation for 2 h at 4uC with monoclonal rat anti-BrdU primary
antibody (AbD Serotec, 1:1000) in PBS-T. Plates were rinsed three
times in PBS, followed by incubation for 30 min at room
temperature in donkey anti-rat biotinylated secondary antibodies
(Jackson Immunoresearch, 1:2000) in PBS-T. After another three
rinses in PBS, plates were incubated 30 min at room temperature
with an avidin-biotin complex (Vectastain Elite kit, Vector
Laboratories). Plates were rinsed in PBS and the label visualized
by incubation at room temperature for 8 min with 3,39-
diaminobenzidine (DAB; 0.04% DAB with 0.012% H2O2 in
PBS). The DAB solution was rinsed off with PBS, and plates were
mounted onto glass microscope slides with an aqueous mounting
medium (glycerine with phenol).
Image Analysis
Cells were counted in digital photomicrographs (two per
sample) taken under a 406objective (Olympus microscope, Scion
Corporation camera, ImageJ software) after processing in a
standardized manner for analysis using Preview software (Apple
Inc.) to uniformly maximize contrast and desaturate the images.
We counted three classes of labelled cells in the resulting images:
strongly labelled (nucleus entirely black), moderately labelled
(nucleus grey with some black spots), and weakly labelled (nucleus
grey with no black spots) (Fig. 1 A–F). We also counted the total
number of cells in images with eliminated highlights and uniformly
enhanced contrast to visualize cell membranes; we only counted
cells (labelled or not) with nuclei entirely visible within the field of
view. The percentage of total visible cells that were labelled was
calculated for each image; data are reported as the average of the
two images for each sample.
Results
Calibration Curves and Threshold Determination
We first exposed cultured cells to decreasing known concentra-
tions of BrdU, to determine the sensitivity of the assay. The
presence of BrdU was detectable for added concentrations from
3 mg/mL down to 5 mg/mL, and weakly detectable at 3 mg/mL
(see Fig. 1A–F). No difference in the density of labelled cells was
observed as a function of whether BrdU was diluted in unlabelled
bird serum, normal horse serum, or 0.9% saline. We therefore
used 0.9% saline as the standard diluent for the dilution curve run
alongside all serum samples.
Relationship between Labelling Index and BrdU
Concentration
We found moderately- and strongly-labelled cells only in
cultures given BrdU at concentrations above 10 mg/mL
(Fig. 1D–F). However, the number of these cells (20–60% of the
total) did not clearly relate to the BrdU concentrations in this
range: saturation was rapidly observed for increasing concentra-
tions (data not shown). When weakly-labelled cells were included
in the total counts, labelled cells were reliably observed at BrdU
concentrations down to 3 mg/mL, and the percentage of labelled
cells was linearly related to the BrdU concentration for concen-
trations up to 50 mg/mL (% labelled cells = (1.65160.115)6BrdU
In Vitro Detection of BrdU in Serum Samples
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conc in mg/mL, p,0.0001, regression forced through (0,0); see
inset of Fig. 1G). The total counts of labelled cells then reached a
plateau at higher concentrations (Fig. 1G). All data are thus
presented as the total of all types of labelled cells (weakly,
moderately, and strongly labelled).
Figure 1. Dose-response curve of labelling index after incubation of HEK293T cells with BrdU. (A–F) Cultured cells stained for BrdU, after
incubation with BrdU at different concentrations (as indicated at the bottom of each image). Images were consistently modified to enhance contrast
and remove colour, and are all shown to the same scale. (A) At very low concentrations, very few cells were labelled even weakly. (B–F) As BrdU
concentration increased, the proportion of visible cells that were weakly-labelled (w), moderately-labelled (m), or strongly-labelled (s) increased. Every
culture plate also contained some unlabelled cells (arrowhead). (G) Total numbers of labelled cells (weakly+moderately+strongly) reached a plateau
with BrdU concentrations above 50 mg/mL; note the break in the x-axis scale. At lower concentrations, however, (inset) there was a strong linear
relationship between BrdU concentration and the total number of labelled cells (Y = 1.651 X, line forced through [0,0]; confidence interval for
slope= 1.403 to 1.898, r = 0.9606, p,0.0001). Dashed lines show 95% confidence interval around the (solid) line of best fit.
doi:10.1371/journal.pone.0063692.g001
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BrdU Clearance from Serum in vivo
No labelled cells were detected in cultures that had been treated
with serum collected at 120 or 240 min after BrdU injection in any of
the three species considered. At these two late time points, BrdU
concentration in serumwas thusbelow3 mg/mLandpresumablynot
sufficient to label cells in vivo in any of the species studied (Fig. 2).
In canaries, at the 15 and 30 min time points, the average
percentage of labelled cells (weakly+moderately+strongly) ranged
between 20 and 40% of the total, although the individual variation in
thispercentagewasrelatively largeespeciallyat the30 min timepoint
(Fig. 2A). Based on the calibration curve presented in the inset of
Figure 1, these percentages of labelled cells were shownto correspond
to BrdU concentrations ranging between 10 and 25 mg/mL (Fig. 2B)
and definitely below 50 mg/mL. The serum concentrations of BrdU
obtained soon after the injection were thus well below the theoretical
maximum blood concentration of 1 mg/mL. Indeed, assuming that
approximately 10% of overall body weight is blood and that all BrdU
enters the blood, an injection of 100 mg BrdU per kg body weight
should correspond to a total injection of approximately 100 mg per
100 mL blood volume, i.e. a concentration of 1 mg/mL. Actual
concentrations detected at 15 min post-injection were thus only 5%
of this maximal theoretical value indicating either a limited
absorption or rapid catabolism.
Labelling of cells was then nearly absent from the canary
samples collected 60 minutes after injection indicating a lack of
BrdU in most of these sera (concentration below 3 mg/mL in all
samples except one 60 min sample). No evidence of a sex
difference in BrdU concentrations could be detected here in
canaries (compare open and filled circles in Fig. 2A) but additional
work should obviously be performed to confirm this impression.
A few serial samples were also able to be collected and assayed
for BrdU in quail and mouse. These results indicate that the
present technique should be applicable to a broad range of species
and suggest a similar rapid clearance of BrdU from the blood of
these species (Fig. 2C–D).
Discussion
We report here a fast, simple, and inexpensive method for
detecting thymidine analogues in serum after injection in various
species by making use of cultured, dividing cells as detectors. Using
this technique we show here that in canaries (and preliminary data
indicate that it is also highly likely to be the case in Japanese quail
and mice), unbound BrdU is cleared from circulating blood within
2 h after intra-peritoneal injection. This is reasonably consistent
with the bioavailability data previously presented for other species
[12–16], [20], [21]. However, after incubation with canary
(Fig. 2A–B; and possibly mouse, Fig. 2D) serum samples collected
60 minutes after BrdU injection, labelled cell counts were already
at a similar low level. This suggests that in this (these) species the
clearance rate of BrdU from serum may be faster than typically
claimed, although this does not preclude the possibility that BrdU
may be sequestered within, and available at low levels for
incorporation in, other tissues including the brain. One quail
sample still contained a high BrdU concentration (around 30 mg/
mL) at 60 min post-injection (Fig. 2C) suggesting lower clearance
in this species but more work would obviously be needed to
confirm this single observation. Species differences in BrdU bio-
availability could relate to body size (250–300 g in quail as
compared to 15–30 g in mice or canaries), to metabolism, or to
species differences in the efficiency either of active pyrimidine
transport or of diffusion from the intraperitoneal cavity into the
circulatory system. Additional species would need to be tested to
further explore these possibilities.
Regardless of the underlying mechanism, that species differ-
ences may exist in the rate at which BrdU enters and/or is
removed from circulation is important to note, as such differences
could bias comparisons across species when counts of labelled cells
in tissue are compared. All other factors being equal, including
in vivo cell proliferation rates, a species with faster clearance of
BrdU (or other thymidine analogue) would appear to have fewer
labelled cells in tissue after injection than a species with a slower
clearance rate, simply due to BrdU not being available for uptake
by cells for the same length of time.
Figure 2. Labelling indices and deduced BrdU concentrations
after incubation of HEK293T cells with serum from BrdU-
injected animals. (A). Percentage (means 6 SD) of the total numbers
of cells visible in culture that were immunoreactive for BrdU after
incubation with serum collected from adult canaries at various times
after BrdU injection. All individual male (black spots) and female (open
circles) data points are represented in the figure. (B) Average
concentrations (means 6 SD) of BrdU in these canary samples based
on the calibration curve illustrated in the inset of Figure 1G. (C–D)
Concentrations of BrdU in blood samples collected in two female
Japanese quail (C) or one male mouse (D) at various times after a single
BrdU injection.
doi:10.1371/journal.pone.0063692.g002
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The bioassay presented here can be used to measure BrdU or any
other thymidine analogue detectable by immunohistochemistry (e.g.
iodo-deoxyuridine [IdU]: [1], [24]; chloro-deoxyuridine
[CldU]:[25–28]; ethynyl-deoxyuridine [EdU]: [29], [30]) in serum
at multiple times after injection. It would allow for the generation of a
time course of BrdU availability in the circulation for any species, and
after any sort of treatment, with the advantages of being rapid and not
requiring much specialized equipment. Injection and serum collec-
tioncanbecompleted inasingleday,whilecellculture incubationand
immunohistochemical staining can be done on the following day.
Although assays were performed here on sera obtained from blood
that was allowed to clot overnight, there is no reason why the same
technique could not be applied on sera centrifuged within minutes of
collection. Furthermore, we used here HEK293T cells as in vitro
detectors for BrdU but these could be readily substituted with any cell
line that multiplies efficiently in culture. It should also be noted that
cells were grown on sterile glass coverslips placed in 24 well plates. If a
cell culture facility is not available in a laboratory interested by this
technique, a collaboration with a laboratory that has this technique
available could thus be easily developed. Once cells have been grown
in sterile conditions on the coverslips, the wells containing these
cultures can easily be covered and transported to a classical histology
laboratory where the 4 hour incubation with samples containing
BrdU and immunohistochemical staining can be performed in
conditions that are no longer sterile. This is actually what was done
here (original culture in sterile conditions and remaining procedures
in a standard histology facility). If detailed analysis is not required and
only a semi-quantitative assessment is needed, a single blood sample
can be taken at 15–30 min after injection, and a simple qualitative
measure (presence/absence) can be obtained as soon as the stained
culture plates are mounted on slides. The entire procedure from
injection to final data analysis can therefore be realistically completed
in less than 2 days.
In conclusion, the method presented here provides a proof of
concept for a technique to investigate the rate of BrdU clearance
in canaries, a species in which pioneering studies of adult
neurogenesis were initiated 30 years ago [22], [23]. This method
can be used to estimate the length of time after injection for which
BrdU is available for incorporation into new cells in any given
vertebrate species. It would allow for the investigation of
differences in pyrimidine uptake and clearance rates between
sexes, or among different developmental stages. It can also
constitute a rapid first step into investigations of experimental
treatment effects in BrdU uptake by, or clearance from, the serum,
particularly treatments that may affect pyrimidine metabolism.
Finally, this method could be easily adapted for detection of any
thymidine analogue for which an appropriate immunohistochem-
ical detection method is available for use in fixed cells. We have
demonstrated the utility of this technique using HEK293T cells to
detect free BrdU in the serum of canaries, quail, and mice at
various time points after BrdU injection. There is, however, no
apparent barrier to using it for detection of any thymidine
analogue normally detectable in tissue, injected into any species
from which serum can be collected, using any proliferative
eukaryotic cell strain that can be cultured.
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